The purpose of the report is to illustrate the state of the market of Gout Therapeutics, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026.
Browse here for full report with Toc: https://www.credenceresearch.com/report/gout-therapeutics-market
Gout is a complex form of inflammatory arthritis characterized by acute intermittent episodes of inflammation and pain. Gout therapeutics market is rapidly growing due to factors such as increasing incidence of gout, significant unmet needs and rising number of obese and geriatric population. Strategic partnership of key players with small manufacturers in the market is expected to drive market growth during forecast period. In April 2016, AstraZeneca entered into licensing agreement with Ironwood Pharmaceuticals, which granted the United States exclusive rights to AstraZeneca for Zurampic (lesinurad) and it is expected that AstraZeneca will successfully promote Zurampic in the United States which would further drive the gout therapeutics market growth.
The market is currently dominated by few players such as Ardea Biosciences Inc., AstraZeneca plc., BioCryst Pharmaceuticals Inc., Cymabay Therapeutics, Inc., GlaxoSmithKline plc., Horizon Pharma Plc., Novartis AG, Regeneron Pharmaceuticals Inc., Sanofi Aventis, Savient Pharmaceuticals, Inc., Selecta Biosciences, Inc., Takeda Pharmaceutical Company Ltd., Teijin Pharma Ltd., and other.
Why was the report written?
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global Gout Therapeutics buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry.
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of Gout Therapeutics contains:
Analysis and forecast of Gout Therapeutics market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the Gout Therapeutics market;
Assessment and forecast of Gout Therapeutics market development;
Financial and business profiles of the leading companies in the Gout Therapeutics industry.
Also you can request us for sample in PDF with depth details and graph: https://www.credenceresearch.com/sample-request/58808
– Up to date working Gout Therapeutics data by major regions in the world, the forecast of planned capacity additions by 2026
– The annual breakdown of capital expenditure spending on proposed Gout Therapeutics for the period 2018 to 2026
– Planned Gout Therapeutics additions and capital expenditure spending by key countries and companies across the world
– Planned capital expenditure spending on new Gout Therapeutics projects by region, key countries, and companies
– Details of major planned Gout Therapeutics projects in the world up to 2026
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Credence Research Inc.
105 N 1st ST #429
Toll Free (US/CANADA): +1-800-361-8290